Genethon to Use Polyplus-transfection’s jetPEI™ Transfection Reagent for Producing Viral Vectors
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Polyplus-transfection SA has announced that Genethon, a not-for-profit biotherapy laboratory run by the French Muscular Dystrophy Association (AFM – Association Française contre les Myopathies) and which is financed by donations raised through the annual Telethon, has selected Polyplus-transfection’s jetPEI™ transfection reagent for the production of its viral vectors. The financial terms of the deal were not disclosed.
Genethon’s mission is to develop gene therapies for the treatment of rare diseases, including neuromuscular pathologies such as Duchenne muscular dystrophy and spinal muscular atrophy. The therapeutic genes identified by the Genethon researchers are delivered by modified viruses. This requires the production of large batches of viral vectors for preclinical research, followed later by batches of clinical-grade material for clinical trials.
Genethon will use the jetPEI transfection reagent in this context to produce adeno-associated viruses (AAV), or lentiviruses, by transient transfection of mammalian cells. This method is used from the research stage through to the production of clinical batches, for which the transfection reagent supplied by Polyplus is delivered with the required quality tests.
“We are delighted that a leading international research facility such as Genethon is using our jetPEI transfection reagent for the production of viral vectors for its research and clinical trials,” said Mark Bloomfield, CEO of Polyplus-transfection. “Polyethylenimine (PEI), the active ingredient of jetPEI, is the ideal reagent for the large scale transfection of animal cells under clinical conditions. Genethon’s choice of jetPEI as its transfection reagent demonstrates its confidence in the efficacy and quality of jetPEI, as well as in our exclusive rights for the use of PEI for transfection.”
“The possibility of using Polyplus-transfection’s jetPEI opens a new avenue for the large-scale production of our viral vectors for all applications where other methods are inappropriate,” said Genethon’s Product Development Director, Mehdi Gasmi. “In addition, the availability of a suitable reagent means we will be able to use jetPEI for producing clinical-grade vectors, which is a big asset in helping Genethon fulfill its mission.”
Genethon’s mission is to develop gene therapies for the treatment of rare diseases, including neuromuscular pathologies such as Duchenne muscular dystrophy and spinal muscular atrophy. The therapeutic genes identified by the Genethon researchers are delivered by modified viruses. This requires the production of large batches of viral vectors for preclinical research, followed later by batches of clinical-grade material for clinical trials.
Genethon will use the jetPEI transfection reagent in this context to produce adeno-associated viruses (AAV), or lentiviruses, by transient transfection of mammalian cells. This method is used from the research stage through to the production of clinical batches, for which the transfection reagent supplied by Polyplus is delivered with the required quality tests.
“We are delighted that a leading international research facility such as Genethon is using our jetPEI transfection reagent for the production of viral vectors for its research and clinical trials,” said Mark Bloomfield, CEO of Polyplus-transfection. “Polyethylenimine (PEI), the active ingredient of jetPEI, is the ideal reagent for the large scale transfection of animal cells under clinical conditions. Genethon’s choice of jetPEI as its transfection reagent demonstrates its confidence in the efficacy and quality of jetPEI, as well as in our exclusive rights for the use of PEI for transfection.”
“The possibility of using Polyplus-transfection’s jetPEI opens a new avenue for the large-scale production of our viral vectors for all applications where other methods are inappropriate,” said Genethon’s Product Development Director, Mehdi Gasmi. “In addition, the availability of a suitable reagent means we will be able to use jetPEI for producing clinical-grade vectors, which is a big asset in helping Genethon fulfill its mission.”
